| Date | Time | Source | | | 06/29/2012 | 4:00PM | BW | IGI Laboratories Announces the Submission of Two More ANDAs
IGI Laboratories, Inc. (NYSE Amex: IG), a New Jersey based formulation and manufacturing company, today announced that it has submitted two additional abbreviated new drug applications (ANDAs) to the US FDA, bringing the company’s total number of submissions to eight. IGI President and CEO Charlie Moore commented, “We... More...>> |
| 06/05/2012 | 8:00AM | BW | IGI Laboratories Announces the Submission of Sixth ANDA
IGI Laboratories, Inc. (NYSE Amex: IG), a New Jersey based formulation and manufacturing company, today announced that it has submitted an additional abbreviated new drug application (ANDA) to the US FDA, bringing the company’s total number of submissions to six. IGI President and CEO Charlie Moore commented, “Our... More...>> |
| 05/15/2012 | 8:00AM | BW | IGI Laboratories Announces 1st Quarter 2012 Results
IGI Laboratories, Inc. (NYSE Amex: IG), a New Jersey based topical generic drug development and manufacturing company, provided its financial results for the first quarter ended March 31, 2012. First Quarter 2012 Highlights vs. 2011 Total revenues of $1.8 million for Q1 2012, an increase of 16% over same quarter in 2011... More...>> |
| 05/04/2012 | 8:00AM | BW | IGI Laboratories to Hold Conference Call for 1st Quarter 2012 Results
IGI Laboratories, Inc. (NYSE Amex: IG), a New Jersey based topical generic drug development and manufacturing company, will hold a conference call at 4:15 pm ET on Tuesday, May 15, 2012 to discuss 1st quarter 2012 results. The Company invites you to listen to the call by dialing 1-866-783-2143. International participants... More...>> |
| 03/20/2012 | 8:00AM | BW | IGI Laboratories Announces 4th Quarter 2011 and Year End 2011 Results
IGI Laboratories, Inc. (NYSE Amex: IG), a New Jersey based topical generic drug development and manufacturing company, provided its financial results for the fourth quarter and year ended December 31, 2011. Fourth Quarter 2011 Highlights vs. 2010 Total Revenues of $2.1 million, increase of 21% over same quarter in 2010... More...>> |
| 03/09/2012 | 3:22PM | BW | IGI Laboratories to Hold Conference Call for 4th Quarter 2011 Results
IGI Laboratories, Inc. (NYSE Amex: IG), a New Jersey based topical generic drug development and manufacturing company, will hold a conference call at 4:30 pm ET on Tuesday, March 20, 2012 to discuss 4th quarter 2011 results. The Company invites you to listen to the call by dialing 1-866-730-5768. International participants... More...>> |
| 12/29/2011 | 8:00AM | BW | IGI Laboratories Announces the Submission of Fifth ANDA
IGI Laboratories, Inc. (NYSE Amex: IG), a New Jersey based formulation and manufacturing company, today announced that it has submitted an additional abbreviated new drug application (ANDA) to the US FDA, bringing the company’s total number of submissions to five. IGI President and CEO Charlie Moore commented, “We... More...>> |
| 12/22/2011 | 8:00AM | BW | IGI Laboratories and NeoStrata Company, Inc. Extend Turnkey Supply Agreement
IGI Laboratories, Inc. (NYSE Amex: IG), a New Jersey based formulation and manufacturing company, and NeoStrata Company, Inc., (www.neostrata.com) headquartered in Princeton, NJ, announced a three-year extension to their Turnkey Manufacturing Services agreement. Under the terms of the extension, IGI Laboratories, Inc... More...>> |
| 12/08/2011 | 8:00AM | BW | IGI Laboratories, Inc. and Medimetriks Pharmaceuticals, Inc. Enter Long Term Strategic Partnership
IGI Laboratories, Inc. (NYSE Amex: IG), a New Jersey based formulation and manufacturing company, today announced that it has entered into a long term strategic partnership with Medimetriks Pharmaceuticals, Inc. This strategic partnership designates IGI Laboratories, Inc. (IGI) as the developer and manufacturer of a family... More...>> |
| 11/21/2011 | 8:00AM | BW | IGI Laboratories Announces the Submission of Two More ANDAs
IGI Laboratories, Inc. (NYSE Amex: IG), a New Jersey based formulation and manufacturing company, today announced that it has submitted two more abbreviated new drug applications (ANDAs) to the US FDA. IGI President and CEO Charlie Moore commented, “We are excited to announce that we successfully developed and submitted... More...>> |
| 11/08/2011 | 8:00AM | BW | IGI Laboratories to Hold Conference Call for 3rd Quarter 2011 Results
IGI Laboratories, Inc. (NYSE Amex: IG), a New Jersey based formulation and manufacturing company, will hold a conference call at 4:30 pm ET on Monday, November 21, 2011 to discuss 3rd quarter 2011 results. The Company invites you to listen to the call by dialing 1-866-510-0712. International participants should call 1-617-597-5380... More...>> |
| 10/24/2011 | 8:00AM | BW | IGI Laboratories, Inc. Ranked Number 23 Fastest Growing Company in the Greater Philadelphia Region on Deloitte’s 2011 Great...
IGI Laboratories, Inc. (NYSE Amex: IG) today announced it ranked 23rd on Deloitte’s 2011 Greater Philadelphia Fast 50 ranking of the 50 fastest growing technology, media, telecommunications, life sciences and clean technology companies in the Greater Philadelphia region. IGI Laboratories grew 133 percent during this... More...>> |
| 08/08/2011 | 4:20PM | BW | IGI Laboratories to Hold Conference Call for 2nd Quarter 2011 Results
IGI Laboratories, Inc. (NYSE Amex: IG), a New Jersey based formulation and manufacturing company, will hold a conference call at 4:30 pm ET on Tuesday, August 16, 2011 to discuss 2nd quarter 2011 results. The Company invites you to listen to the call by dialing 1-866-203-3436. International participants should call 1-617-213-8849... More...>> |
| 07/15/2011 | 10:57AM | BW | IGI Laboratories Appoints Jenniffer Collins to CFO
IGI Laboratories, Inc. (NYSE Amex: IG), a New Jersey based pharmaceutical company, today announced that Jenniffer Collins has been appointed Chief Financial Officer of IGI Laboratories Inc. effective July 21, 2011. Charles Moore, President and CEO, commented, “We are pleased to welcome Jenniffer to the IGI team. She... More...>> |
| 06/14/2011 | 4:53PM | BW | CORRECTING and REPLACING TriPoint Global Research Publishes Research Report on IGI, Laboratories, Inc.
Please replace the release with the following corrected version due to multiple revisions. The corrected release reads: TRIPOINT GLOBAL RESEARCH PUBLISHES RESEARCH REPORT ON IGI, LABORATORIES, INC. TriPoint Global Research publishes Research Report on IGI, Laboratories, Inc. by Senior Analysts Richard W West, CFA and Sherry... More...>> |
| 06/14/2011 | 3:25PM | BW | TriPoint Global Research Publishes Research Report on IGI, Laboratories, Inc.
TriPoint Global Research publishes Research Report on IGI, Laboratories, Inc. (Amex: IG) by Senior Analysts Richard W West, CFA and Sherry Grisewood, CFA Industry: Pharmaceuticals & Biotechnology Current Rating: Market Perform Rating Assigned: 6/14/2011 Analyst: Richard W West, CFA and Sherry Grisewood, CFA A 23-page Research... More...>> |
| 06/07/2011 | 5:30PM | BW | IGI Laboratories to Hold Conference Call for Management Update
IGI Laboratories, Inc. (NYSE Amex: IG), a New Jersey based formulation and manufacturing company, will hold a management update conference call at 4:00 pm ET on Wednesday, June 15, 2011. The Company invites you to listen to the call by dialing 1-888-396-2386. International participants should call 1-617-847-8712. The passcode... More...>> |
| 01/10/2011 | 4:45PM | BW | IGI Laboratories Announces Second ANDA Submission
IGI Laboratories, Inc. (NYSE Amex: IG), a New Jersey based formulation and manufacturing company, today announced that it has submitted its second abbreviated new drug application (ANDA) to the US FDA. IGI President and CEO Charlie Moore commented, “We are proud to report that we are executing our strategy of developing... More...>> |
| 12/08/2010 | 4:12PM | BW | IGI Laboratories Raises $6.5 Million Through Private Placement
IGI Laboratories, Inc. (NYSE Amex:IG) today announced that it has raised $6,500,000 through a private placement financing in which it sold common stock at $1.10 per share. Charles Moore, the Company’s CEO, commented that, “We are happy to have completed this financing, the proceeds of which we will utilize for working... More...>> |
| 11/30/2010 | 4:45PM | BW | IGI Laboratories, Inc. Announces Bhaskar Chaudhuri’s Appointment to Its Board of Directors
IGI Laboratories, Inc. (NYSE Amex:IG). IGI Laboratories, Inc. (the “Company”) is pleased to announce the appointment of Bhaskar Chaudhuri to its board of directors commencing December 1, 2010. Mr. Chaudhuri has more than 20 years experience in pharmaceutical management, research and development. Mr. Chaudhuri holds... More...>> |
|
